[
  {
    "ts": "2025-12-24T01:09:57+00:00",
    "headline": "Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer's (PFE) Risk–Reward Story?",
    "summary": "Earlier in December 2025, Pfizer disclosed that a participant in its long-term Hympavzi hemophilia trial died following serious cerebrovascular complications, while also tightening revenue guidance for 2025 and issuing an initial outlook for 2026 that reflects ongoing patent and pricing headwinds. At the same time, Pfizer is leaning heavily on its oncology and immunology pipeline, including positive Phase 3 data for TUKYSA and PADCEV combinations and new AI-enabled and TCR-focused...",
    "url": "https://finance.yahoo.com/news/did-hympavzi-trial-death-tighter-010957190.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e76ec5b2-82a5-35c9-bb87-c6ddc0de0c11",
      "content": {
        "id": "e76ec5b2-82a5-35c9-bb87-c6ddc0de0c11",
        "contentType": "STORY",
        "title": "Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer's (PFE) Risk–Reward Story?",
        "description": "",
        "summary": "Earlier in December 2025, Pfizer disclosed that a participant in its long-term Hympavzi hemophilia trial died following serious cerebrovascular complications, while also tightening revenue guidance for 2025 and issuing an initial outlook for 2026 that reflects ongoing patent and pricing headwinds. At the same time, Pfizer is leaning heavily on its oncology and immunology pipeline, including positive Phase 3 data for TUKYSA and PADCEV combinations and new AI-enabled and TCR-focused...",
        "pubDate": "2025-12-24T01:09:57Z",
        "displayTime": "2025-12-24T01:09:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-hympavzi-trial-death-tighter-010957190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-hympavzi-trial-death-tighter-010957190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T01:00:00+00:00",
    "headline": "Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025",
    "summary": "Continued revenue growth and commercial projects fuel Telescope's successful intelligent automation and advanced chemical manufacturing portfolioVancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (\"Telescope Innovations\", \"Telescope\", or the \"Company\"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The...",
    "url": "https://finance.yahoo.com/news/telescope-innovations-reports-significant-milestones-010000828.html",
    "source": "Newsfile",
    "provider": "yfinance",
    "raw": {
      "id": "e6270154-f988-3a77-8b1e-f32f2b12cf4f",
      "content": {
        "id": "e6270154-f988-3a77-8b1e-f32f2b12cf4f",
        "contentType": "STORY",
        "title": "Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025",
        "description": "",
        "summary": "Continued revenue growth and commercial projects fuel Telescope's successful intelligent automation and advanced chemical manufacturing portfolioVancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (\"Telescope Innovations\", \"Telescope\", or the \"Company\"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The...",
        "pubDate": "2025-12-24T01:00:00Z",
        "displayTime": "2025-12-24T01:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/newsfile_64/291022af76aac16de13b9d0aa6027c57",
          "originalWidth": 550,
          "originalHeight": 712,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4vm2omfDOTLV0jqOmGQ.w--~B/aD03MTI7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/291022af76aac16de13b9d0aa6027c57.cf.webp",
              "width": 550,
              "height": 712,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/azdcZhXs6lg7lAieorWiZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/291022af76aac16de13b9d0aa6027c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Newsfile",
          "url": "https://www.newsfilecorp.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/telescope-innovations-reports-significant-milestones-010000828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/telescope-innovations-reports-significant-milestones-010000828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TELIF"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T16:20:00+00:00",
    "headline": "PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth",
    "summary": "Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.",
    "url": "https://finance.yahoo.com/news/pfes-oncology-obesity-pipeline-position-162000310.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a89a21b0-4158-368a-8375-a69745a3275a",
      "content": {
        "id": "a89a21b0-4158-368a-8375-a69745a3275a",
        "contentType": "STORY",
        "title": "PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth",
        "description": "",
        "summary": "Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.",
        "pubDate": "2025-12-24T16:20:00Z",
        "displayTime": "2025-12-24T16:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w5T7o1LHfvUowVKdWOi4Rg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3L0ANckA9Qf5lXTiNAgdWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfes-oncology-obesity-pipeline-position-162000310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfes-oncology-obesity-pipeline-position-162000310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T22:46:00+00:00",
    "headline": "Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever",
    "summary": "If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.",
    "url": "https://www.fool.com/investing/2025/12/24/got-1000-high-yield-healthcare-stocks-buy-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "727ca8e3-ac25-33d3-8de8-b180eb99424d",
      "content": {
        "id": "727ca8e3-ac25-33d3-8de8-b180eb99424d",
        "contentType": "STORY",
        "title": "Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever",
        "description": "",
        "summary": "If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.",
        "pubDate": "2025-12-24T22:46:00Z",
        "displayTime": "2025-12-24T22:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4f8869574744033c34efaa49f3a3a097",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person holding a piggy bank with a thinking or questioning expression on their face.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/olBIqlEjH10icEaYwkCI9g--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4f8869574744033c34efaa49f3a3a097.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e97iK_tKSTBWjofSHUQc.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4f8869574744033c34efaa49f3a3a097.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/24/got-1000-high-yield-healthcare-stocks-buy-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/got-1-000-2-high-224600689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]